期刊论文

Lin, S.-H.

英文

药学学报(英文)

2211-3835

2023

13

1

157-173

10.1016/j.apsb.2022.05.019

This work was supported by grants from the Natural Science Foundation of Tianjin ( 21JCZDJC00060 , China), the National Nature Science Foundation of China ( 81973356 , 91957120 , 81902826 , and 81672781 ), the Fundamental Research Funds for the Central Universities of Nankai University ( 3206054 , 91923101 , 63213082 and 92122017 , China), the State Key Laboratory of Drug Research ( SIMM2105KF-08 , China), the National Key R&D Program of China (No. 2018YFC2002000 ), the Innovative S&T Projects for Young Researchers of Tianjin Academy of Agricultural Science (grant No. 201918 , China), and the Natural Science Foundation of Tianjin ( 19JCYBJC29600 and 21JCYBJC00180 , China). We also thanks for Lu Zhou (Fudan University, Shanghai, China) for suggestion on analyzing the structural for 6PGD R324 site.

本校为其他机构

Metabolic reprogramming is a hallmark of cancer, including lung cancer. However, the exact underlying mechanism and therapeutic potential are largely unknown. Here we report that protein argi-nine methyltransferase 6 (PRMT6) is highly expressed in lung cancer and is required for cell metabolism, tumorigenicity, and cisplatin response of lung cancer. PRMT6 regulated the oxidative pentose phosphate pathway (PPP) flux and glycolysis pathway in human lung cancer by increasing the activity of 6-phospho-gluconate dehydrogenase (6PGD) and a-enolase (ENO1). Furthermore, PRMT6 methylated R324 of 6PGD t...